// App-Quantinova.ai

8539 : Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL).

Researchers

Presenter

  • Florian Scherer

Principal Investigators

  • Michael Richard Green

  • Colm Keane

  • Katherine A Kong

  • Malek Faham

  • Mark S. Hertzberg

  • Maher K Gandhi

  • Ranjana H. Advani

  • Ronald Levy

  • Maximilian Diehn

  • Li Zhou

  • Rashi Krishnan

  • Chih Long Liu

  • Cynthia Glover

  • Robert S. Ohgami

  • Rodney J Hicks

  • Ash A. Alizadeh

  • Aaron M. Newman

  • Daniel M. Klass

Medical Centers

  • Princess Alexandra Hospital, Brisbane, Australia

  • Division of Oncology, Stanford University School of Medicine, Stanford, CASequenta, Inc., South San Francisco, CAUniversity of Nebraska Medical Center, Omaha, NE

  • Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA

  • Westmead Hospital, Sydney, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Stanford Univ Med Ctr, San Carlos, CA

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Circulating tumor cells

  • Circulating DNA

  • Plasma cell-free DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved